You are here

Innovative Design and Synthesis of Antiparasitic Agents

Award Information
Agency: Department of Defense
Branch: Army
Contract: N/A
Agency Tracking Number: 36712
Amount: $95,232.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Texas Research Park, 14785 Omicron Dr
San Antonio, TX 78245
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Irach B. Taraporewala
 (210) 677-6001
Business Contact
Phone: () -
Research Institution
N/A
Abstract

This Phase I project pertains to the synthesis and biological evaluation of novel L-nucleoside-derived antimalarial compounds. A major recent finding has been that during the development of the malaria parasite in the host erythrocyte, profound alterations are caused in the permeability of the host cell-membrane. Recent investigations have discovered that a new transport pathway for nucleosides is induced by the parasite in the host cell membrane. This system is significantly different to any transport system in the host, and has opened the way for the design of selective new antimalarial drugs which cannot enter the host cell membrane (such as L-nucleoside conjugates with cytotoxic drugs). These compounds have the propensity to be toxic to the parasite without affecting the host cell. The development of this new approach to malaria chemotherapy is of major significance, as these compounds act by different mechanisms of action from conventional quinoline or acridine antimalarial drugs, and therefore should show no cross-resistance. At least thirty test compounds based on this concept will be synthesized and evaluated in Phase I studies. Compounds will be screened for activity against Plasmodium falciparum and their transport and mechanisms of action will be studied. Test compounds will also be submitted to the U.S. Army's antimalarial testing program. The project will likely produce a new class of antimalarial drugs for treatment of multi-drug resistant malaria. The disease kills over 2 million persons worldwide annually and affects over 300 million. There is therefore a considerable humanitarian benefit as well as commercial potential upon successful completion of the project goals.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government